Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
Patent 4571385 Issued on February 18, 1986. Estimated Expiration Date: 
June 27, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
June 27, 2003. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesTemperature-sensitive recombinant mutant viruses and a process for producing same Cultivatable human rotavirus type 2 Patent #: 4341870 Inventors
AssigneeApplicationNo. 06/508323 filed on 06/27/1983US Classes:435/456, The polynucleotide is encapsidated within a virus or viral coat424/205.1, Reassortant or deletion mutant virus424/215.1, Reoviridae (e.g., rotavirus, reovirus, orbivirus, avian proventriculitis virus, bluetongue virus, Colorado tick fever virus, etc.)435/236, Inactivation or attenuation; producing viral subunits435/237, By serial passage of virus530/388.3, Binds virus or component or product thereof (e.g., virus-associated antigen, etc.)530/389.4, Binds virus or component or product thereof (e.g., virus-associated antigen, etc.)536/23.1DNA or RNA fragments or modified forms thereof (e.g., genes, etc.)ExaminersPrimary: Wiseman, Thomas G.Assistant: Tarcza, John E. Attorney, Agent or FirmInternational ClassesA61K 39/15 (20060101)C12N 7/04 (20060101) AbstractThis invention relates to processes which are used to produce, isolate, and characterize human rotavirus/animal rotavirus reassortants and to produce live attenuated vaccines and vaccine precursors. In the present strategy there is involved the new use of either (1) high titer hyperimmune antisera or (2) monoclonal antisera to select reassortants with the desired human phenotype. A point of novelty is the finding that antiserum or monoclonal antisera alone, so long as it possesses high titer neutralizing activity against only the 34-38Kd glycoprotein or of the animal parent, is sufficient to use for selection of reassortant rotaviruses with human phenotype. Also, the novel products are live attenuated vaccine precursors and vaccines.Other References
|
| ||||||||||||||
